Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation

Katarzyna Lipa, Magdalena Julia Jabłońska, Patryk Kaczor, Kamil Leis, Krystian Kałużny, Przemysław Gałązka


Sofosbuvir is a drug, which has been found useful in HCV (Hepatis C Virus) therapy. It replaced the previously used interferon, the applied of which has shown many side effects or lack of response to treatment. The usage of sofosbuvir with ribavirin shortens the time of treatment and minimizes the number of side effects. It is taken as a single dose of 400 mg for 12 or 24 weeks. The only place of activation of this prodrug is hepatocytes, where its active metabolite is formed (GS-461203). It should not be used together with P-glycoprotein inductors that can reduce the efficiency of its action and with amiodarone, because application of both of them together slows down the heart rate. Numerous tests have demonstrated the effectiveness of sofosbuvir in the treatment of patients who have relapsed disease after liver transplantation. A high percentage of sustained virologic response obtained in all phases of clinical trials has proven the efficacy of sofosbuvir in combination with ribavirin or another HCV drug in the therapy of hepatitis C infection.


sofosbuvir; Hepatis C Virus; liver transplant

Full Text:



Pawlotsky, Jean-Michel, et al. "EASL recommendations on treatment of hepatitis C 2015." J hepatol 63.1 (2015): 199-236.

Food, F. D. A. U. S. "Drug Administration. FDA news release. FDA approves Epclusa for treatment of chronic hepatitis C virus infection [press release][Internet]. Silver Spring: United States Food and Drug Administration; 2016 [cited 2017 Jan 26].”

Poynard, Thierry, et al. "Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration." Hepatology 24.4 (1996): 778-789.

Lawitz, Eric, et al. "Sofosbuvir for previously untreated chronic hepatitis C infection." New England Journal of Medicine 368.20 (2013): 1878-1887.

Pol, Stanislas, Marion Corouge, and Anaïs Vallet-Pichard. "Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life." Hepatic medicine: evidence and research 8 (2016): 21-26

Fung, Amy, et al. "Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against HCV polymerase." Antimicrobial agents and chemotherapy(2014): AAC-02666.; doi: 10.1128/AAC.02666-14

Murakami, Eisuke, et al. "Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977." Journal of biological chemistry (2010): jbc-M110.; doi: 10.1074/jbc.M110.161802

Bhatia, Harmeet Kaur, et al. "Sofosbuvir: a novel treatment option for chronic hepatitis C infection." Journal of pharmacology & pharmacotherapeutics5.4 (2014): 278-284

Cuenca-Lopez, Francisca, Antonio Rivero, and Antonio Rivero-Juárez. "Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C." Expert opinion on drug metabolism & toxicology 13.1 (2017): 105-112.

Kirby, Brian J., et al. "Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir." Clinical pharmacokinetics 54.7 (2015): 677-690.

Kirby, Brian, et al. "Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (gs-331007) in Healthy and HCV infected Adult Subjects: 1106." Hepatology 58 (2013): 746A-747A.

Sokolowska, J., K. Urbanska, and D. Klosinska. "Rola glikoproteiny P w warunkach fizjologicznych iw stanach patologicznych. Część I. Budowa chemiczna i biologiczna rola glikoproteiny P." Życie Weterynaryjne 89.11 (2014).

Back, David J., and David M. Burger. "Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned." Gastroenterology 149.6 (2015): 1315-1317.

Kirby, B., et al. "GS-7977 & HIV ARTs PK—no clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers." 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 2012.

Karageorgopoulos, Drosos E., et al. "Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection." Current opinion in infectious diseases 27.1 (2014): 36-45.

Spera, Anna Maria, et al. "Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?." World journal of hepatology 8.12 (2016): 557-565

Hussar, Daniel A., and Zhimeng Jenny Jin. "New drugs: simeprevir, sofosbuvir, and dolutegravir sodium." Journal of the American Pharmacists Association 54.2 (2014): 202-207.

Forns, Xavier, et al. "Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation." Hepatology 61.5 (2015): 1485-1494.

Fontana, R. J., et al. "Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C." American Journal of Transplantation 13.6 (2013): 1601-1605.

Sulkowski, Mark S., et al. "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection." New England Journal of Medicine370.3 (2014): 211-221.

Poordad, Fred, et al. "Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence." Hepatology 63.5 (2016): 1493-1505.

Kwok, Ryan M., et al. "Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients." Liver Transplantation 22.11 (2016): 1536-1543.

Manns, Michael, et al. "Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial." The Lancet Infectious Diseases 16.6 (2016): 685-697.

Levitsky, Josh, et al. "Perioperative ledipasvir–sofosbuvir for HCV in liver-transplant recipients." New England Journal of Medicine 375.21 (2016): 2106-2108.

Lawitz, Eric, et al. "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study." The Lancet 384.9956 (2014): 1756-1765.

Curry, Michael P., et al. "Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study." Gastroenterology 148.1 (2015): 100-107.

Osinusi, Anuoluwapo, et al. "Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial." Jama 310.8 (2013): 804-811.

Rodriguez-Torres, Maribel, et al. "Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial." Journal of hepatology 58.4 (2013): 663-668.

Lawitz, Eric, et al. "Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial." The Lancet infectious diseases 13.5 (2013): 401-408.

Kowdley, Kris V., et al. "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial." The Lancet 381.9883 (2013): 2100-2107.

Gane, Edward J., et al. "Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C." New England Journal of Medicine 368.1 (2013): 34-44.

Gane, Edward J., et al. "Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection." Gastroenterology 146.3 (2014): 736-743.

Lawitz, Eric, et al. "Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial." The Lancet 383.9916 (2014): 515-523.

Stedman, Catherine. "Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential." Therapeutic advances in gastroenterology 7.3 (2014): 131-140.

Jacobson, Ira M., et al. "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options." New England Journal of Medicine 368.20 (2013): 1867-1877.



  • There are currently no refbacks.

Copyright (c) 2018 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski